These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 23928760)

  • 41. Expensive cancer therapies: unintended effects.
    Delude CM
    J Natl Cancer Inst; 2015 Jan; 107(1):497. PubMed ID: 25564602
    [No Abstract]   [Full Text] [Related]  

  • 42. 340B Drug Pricing Program: The Expansion and Its Effect on Cancer Care.
    Fauer A; Friese CR
    Clin J Oncol Nurs; 2019 Apr; 23(2):217-219. PubMed ID: 30880808
    [TBL] [Abstract][Full Text] [Related]  

  • 43. "It's the economy, stupid": strategies for improved cost containment in cancer treatment.
    Sleijfer S
    Clin Pharmacol Ther; 2014 Apr; 95(4):365-7. PubMed ID: 24646487
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Key factors impacting the delivery and financing of oncology care in the United States.
    Goldsmith PJ; Paivanas T
    J Natl Compr Canc Netw; 2006 May; 4(5):434-7. PubMed ID: 16715607
    [No Abstract]   [Full Text] [Related]  

  • 45. Managing oncology drug costs in a constrained environment.
    Clark P
    Clin Adv Hematol Oncol; 2019 Feb; 17(2):90-93. PubMed ID: 30845110
    [No Abstract]   [Full Text] [Related]  

  • 46. Oncology drug pricing structure is broken.
    Hutchinson L
    Nat Rev Clin Oncol; 2015 Sep; 12(9):499. PubMed ID: 26309071
    [No Abstract]   [Full Text] [Related]  

  • 47. How state and federal policies as well as advances in genome science contribute to the high cost of cancer drugs.
    Ramsey SD
    Health Aff (Millwood); 2015 Apr; 34(4):571-5. PubMed ID: 25847638
    [TBL] [Abstract][Full Text] [Related]  

  • 48. This is a call to oncologists for action.
    Micó C; Berrocal A; Blasco A; Caballero C; Iranzo V; Lobo M; Camps C
    Clin Transl Oncol; 2018 Dec; 20(12):1493-1501. PubMed ID: 29796999
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost issues in new disease-modifying treatments for advanced cancer: in-depth interviews with physicians.
    de Kort SJ; Kenny N; van Dijk P; Gevers S; Richel DJ; Willems DL
    Eur J Cancer; 2007 Sep; 43(13):1983-9. PubMed ID: 17616456
    [TBL] [Abstract][Full Text] [Related]  

  • 50. American Society of Clinical Oncology Position Statement on Addressing the Affordability of Cancer Drugs.
    American Society of Clinical Oncology
    J Oncol Pract; 2018 Mar; 14(3):187-192. PubMed ID: 29091534
    [No Abstract]   [Full Text] [Related]  

  • 51. The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is Unbearable.
    Prasad V; Mailankody S
    Mayo Clin Proc; 2016 Jun; 91(6):707-12. PubMed ID: 27261866
    [No Abstract]   [Full Text] [Related]  

  • 52. Oral/infusion cancer drug parity begins to raise health plan costs.
    Carroll J
    Manag Care; 2012 Jan; 21(1):7-8. PubMed ID: 22334937
    [No Abstract]   [Full Text] [Related]  

  • 53. Why clinical oncologists should talk about the price of cancer drugs.
    Berlinger N
    Virtual Mentor; 2013 Aug; 15(8):677-80. PubMed ID: 23937783
    [No Abstract]   [Full Text] [Related]  

  • 54. Managed care & medical oncology: the focus is on value.
    Danielson E; Demartino J; Mullen JA
    J Natl Compr Canc Netw; 2010 Sep; 8 Suppl 7():S28-37. PubMed ID: 20947721
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Introduction and commentary: Paving the way for biosimilars in oncology.
    Abraham J
    Semin Oncol; 2013 Dec; 40 Suppl 1():S1-4. PubMed ID: 24267943
    [No Abstract]   [Full Text] [Related]  

  • 56. Monthly and Median Costs of Cancer Drugs at the Time of FDA Approval 1965-2016.
    J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 29117395
    [No Abstract]   [Full Text] [Related]  

  • 57. Managing oncology costs.
    Reeder CE; Gordon D
    Am J Manag Care; 2006 Feb; 12(1 Suppl):S3-16; quiz S17-9. PubMed ID: 16478368
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacoeconomic and clinical outcomes in oncology using oral chemotherapy.
    Navarro RP; Morrow T; Baran R
    Manag Care Interface; 2002 Jul; 15(7):55-62. PubMed ID: 12143298
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reimbursement: current status and future outlook.
    Bailes JS
    Semin Oncol; 1994 Aug; 21(4 Suppl 7):118-22. PubMed ID: 8091237
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of the ASCO Value Framework for Anticancer Drugs at an Academic Medical Center.
    Wilson L; Lin T; Wang L; Patel T; Tran D; Kim S; Dacey K; Yuen C; Kroon L; Brodowy B; Rodondi K
    J Manag Care Spec Pharm; 2017 Feb; 23(2):163-169. PubMed ID: 28125363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.